Tanaka Satoru, Ikari Ayana, Nitta Toshikatsu, Horiuchi Tetsuya
Breast Surgery, National Hospital Organization Osaka-Minami Medical Center, Kawachinagano-shi, Osaka, Japan.
Breast Surgery, Shiroyama Hospital, Habikino-shi, Osaka, Japan.
Oxf Med Case Reports. 2017 Jul 6;2017(7):omx038. doi: 10.1093/omcr/omx038. eCollection 2017 Jul.
Trastuzumab improves clinical outcomes in patients with human epidermal growth factor receptor-2-positive breast cancer. However, cardiotoxicity is a potentially important concern, and the long-term cardiac effects of trastuzumab therapy remain unclear. Although reduction of cardiac function by trastuzumab is mostly reversible, some patients, especially those with cardiac risk factors, may rarely experience chronic heart failure or prolonged left ventricular ejection fraction reduction. There have been no detailed published analyses of patients with such unfavorable clinical courses. We report the rare case of a metastatic breast cancer in a woman without cardiac risk factors who experienced long-term irreversible cardiotoxicity after discontinuation of trastuzumab therapy.
曲妥珠单抗可改善人表皮生长因子受体2阳性乳腺癌患者的临床预后。然而，心脏毒性是一个潜在的重要问题，曲妥珠单抗治疗的长期心脏影响仍不清楚。虽然曲妥珠单抗导致的心脏功能下降大多是可逆的，但一些患者，尤其是有心脏危险因素的患者，可能很少会出现慢性心力衰竭或左心室射血分数长期降低的情况。目前尚无关于此类不良临床病程患者的详细公开分析报告。我们报告了一例罕见病例，一名无心脏危险因素的女性转移性乳腺癌患者，在停用曲妥珠单抗治疗后出现了长期不可逆的心脏毒性。
